These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 38801884)

  • 1. Inhibition of ribonucleotide reductase subunit M2 enhances the radiosensitivity of metastatic pancreatic neuroendocrine tumor.
    Chow Z; Johnson J; Chauhan A; Jeong JC; Castle JT; Izumi T; Weiss H; Townsend CM; Schrader J; Anthony L; Yang ES; Evers BM; Rychahou P
    Cancer Lett; 2024 Aug; 596():216993. PubMed ID: 38801884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of the ATR-CHK1 Pathway in Ewing Sarcoma Cells Causes DNA Damage and Apoptosis via the CDK2-Mediated Degradation of RRM2.
    Koppenhafer SL; Goss KL; Terry WW; Gordon DJ
    Mol Cancer Res; 2020 Jan; 18(1):91-104. PubMed ID: 31649026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osalmid, a Novel Identified RRM2 Inhibitor, Enhances Radiosensitivity of Esophageal Cancer.
    Tang Q; Wu L; Xu M; Yan D; Shao J; Yan S
    Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1368-1379. PubMed ID: 32763454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. P53 suppresses ribonucleotide reductase via inhibiting mTORC1.
    He Z; Hu X; Liu W; Dorrance A; Garzon R; Houghton PJ; Shen C
    Oncotarget; 2017 Jun; 8(25):41422-41431. PubMed ID: 28507282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. mTOR kinase inhibition reduces tissue factor expression and growth of pancreatic neuroendocrine tumors.
    Lewis CS; Elnakat Thomas H; Orr-Asman MA; Green LC; Boody RE; Matiash K; Karve A; Hisada YM; Davis HW; Qi X; Mercer CA; Lucas FV; Aronow BJ; Mackman N; Versteeg HH; Bogdanov VY
    J Thromb Haemost; 2019 Jan; 17(1):169-182. PubMed ID: 30472780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implication of checkpoint kinase-dependent up-regulation of ribonucleotide reductase R2 in DNA damage response.
    Zhang YW; Jones TL; Martin SE; Caplen NJ; Pommier Y
    J Biol Chem; 2009 Jul; 284(27):18085-95. PubMed ID: 19416980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting IGF Perturbs Global Replication through Ribonucleotide Reductase Dysfunction.
    Rieunier G; Wu X; Harris LE; Mills JV; Nandakumar A; Colling L; Seraia E; Hatch SB; Ebner DV; Folkes LK; Weyer-Czernilofsky U; Bogenrieder T; Ryan AJ; Macaulay VM
    Cancer Res; 2021 Apr; 81(8):2128-2141. PubMed ID: 33509941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DHS (trans-4,4'-dihydroxystilbene) suppresses DNA replication and tumor growth by inhibiting RRM2 (ribonucleotide reductase regulatory subunit M2).
    Chen CW; Li Y; Hu S; Zhou W; Meng Y; Li Z; Zhang Y; Sun J; Bo Z; DePamphilis ML; Yen Y; Han Z; Zhu W
    Oncogene; 2019 Mar; 38(13):2364-2379. PubMed ID: 30518875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oleandrin enhances radiotherapy sensitivity in lung cancer by inhibiting the ATM/ATR-mediated DNA damage response.
    Wu Q; Liu X; Wang LM; Yang YH; Pan LF; Zhang JJ; Wang YQ; Yao QH; Ma SL; Zhang SR
    Phytother Res; 2024 Aug; 38(8):4151-4167. PubMed ID: 39136618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ATR-CHK1-E2F3 signaling transactivates human ribonucleotide reductase small subunit M2 for DNA repair induced by the chemical carcinogen MNNG.
    Gong C; Liu H; Song R; Zhong T; Lou M; Wang T; Qi H; Shen J; Zhu L; Shao J
    Biochim Biophys Acta; 2016 Apr; 1859(4):612-26. PubMed ID: 26921499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A functional approach reveals a genetic and physical interaction between ribonucleotide reductase and CHK1 in mammalian cells.
    Taricani L; Shanahan F; Malinao MC; Beaumont M; Parry D
    PLoS One; 2014; 9(11):e111714. PubMed ID: 25375241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ribonucleotide Reductase Requires Subunit Switching in Hypoxia to Maintain DNA Replication.
    Foskolou IP; Jorgensen C; Leszczynska KB; Olcina MM; Tarhonskaya H; Haisma B; D'Angiolella V; Myers WK; Domene C; Flashman E; Hammond EM
    Mol Cell; 2017 Apr; 66(2):206-220.e9. PubMed ID: 28416140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BIBR1532, a Selective Telomerase Inhibitor, Enhances Radiosensitivity of Non-Small Cell Lung Cancer Through Increasing Telomere Dysfunction and ATM/CHK1 Inhibition.
    Ding X; Cheng J; Pang Q; Wei X; Zhang X; Wang P; Yuan Z; Qian D
    Int J Radiat Oncol Biol Phys; 2019 Nov; 105(4):861-874. PubMed ID: 31419512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gambogic acid sensitizes gemcitabine efficacy in pancreatic cancer by reducing the expression of ribonucleotide reductase subunit-M2 (RRM2).
    Xia G; Wang H; Song Z; Meng Q; Huang X; Huang X
    J Exp Clin Cancer Res; 2017 Aug; 36(1):107. PubMed ID: 28797284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The translational repressor 4E-BP1 regulates RRM2 levels and functions as a tumor suppressor in Ewing sarcoma tumors.
    Goss KL; Koppenhafer SL; Waters T; Terry WW; Wen KK; Wu M; Ostergaard J; Gordon PM; Gordon DJ
    Oncogene; 2021 Jan; 40(3):564-577. PubMed ID: 33191406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine.
    Duxbury MS; Ito H; Zinner MJ; Ashley SW; Whang EE
    Oncogene; 2004 Feb; 23(8):1539-48. PubMed ID: 14661056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell-cycle-dependent phosphorylation of RRM1 ensures efficient DNA replication and regulates cancer vulnerability to ATR inhibition.
    Shu Z; Li Z; Huang H; Chen Y; Fan J; Yu L; Wu Z; Tian L; Qi Q; Peng S; Wei C; Xie Z; Li X; Feng Q; Sheng H; Li G; Wei D; Shan C; Chen G
    Oncogene; 2020 Aug; 39(35):5721-5733. PubMed ID: 32712628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of ATR potentiates the cytotoxic effect of gemcitabine on pancreatic cancer cells through enhancement of DNA damage and abrogation of ribonucleotide reductase induction by gemcitabine.
    Liu S; Ge Y; Wang T; Edwards H; Ren Q; Jiang Y; Quan C; Wang G
    Oncol Rep; 2017 Jun; 37(6):3377-3386. PubMed ID: 28440428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HPV31 utilizes the ATR-Chk1 pathway to maintain elevated RRM2 levels and a replication-competent environment in differentiating Keratinocytes.
    Anacker DC; Aloor HL; Shepard CN; Lenzi GM; Johnson BA; Kim B; Moody CA
    Virology; 2016 Dec; 499():383-396. PubMed ID: 27764728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CHK1 inhibition sensitizes pancreatic cancer cells to gemcitabine via promoting CDK-dependent DNA damage and ribonucleotide reductase downregulation.
    Liang M; Zhao T; Ma L; Guo Y
    Oncol Rep; 2018 Mar; 39(3):1322-1330. PubMed ID: 29286153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.